Abstract
Biomarkers have proven powerful for target identification, understanding disease progression, drug safety and treatment responses in drug development. Recent development of omics technology has offered great opportunities for identifications of omics biomarkers at low cost. Although biomarkers have brought many promises to drug development, steep challenges arise due to high dimensionality of data, complexity of technology and lack of full understanding of biology. In this article, the application of omics data in drug development will be reviewed. A genome wide association study (GWAS) will be presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benjamini, Y., Hochberg, Y.: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. 57(1), 289–300 (1995)
Biomarkers Definition Working Group Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Therapeutics. 69, 89–95 (2001)
Collins, F.S., Varmus, H.: A new initiative on precision medicine. N. Engl. J. Med. 372(9), 793–795 (2015)
Conover, W.J.: Practical Nonparametric Statistics. John Wiley Chichester, New York (1999)
Fadista, J., Manning, A., Florez, J., Groop, L.: The (in)famous GWAS P-value threshold revisited and updated for low-frequency variants. Eur. J. Hum. Genet. 24, 1202–1205 (2016)
Fleming, T.R., DeMets, D.L.: Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125(7), 605–613 (1996)
Gosho, M., Nagashima, K., Sato, Y.: Study designs and statistical analyses for biomarker research. Sensors 12, 8966–8986 (2012)
Johnstone, I., Titterington, D.: Statistical challenges of high-dimensional data. Phil. Trans. R. Soc. A 367, 4237–4253 (2009)
Kang, H.M., Zaitlen, N.A., Wade, C.M., Kirby, A., Heckerman, D., et al.: Efficient control of population structure in model organism association mapping. Genetics 178, 1709–1723 (2008)
Katz, R.: Biomarkers and Surrogate Markers: an FDA Perspective. NeuroRx 1(2), 189–195 (2004)
Knijnenburg, T.A., Wessels, L.F., Reinders, M.J., Shmulevich, I.: Fewer permutations, more accurate P-values. Bioinformatics 25, i161–i168 (2009)
Meienberg, J., Bruggmann, R., Oexle, K., Matyas, G.: Clinical sequencing: is WGS the better WES? Hum. Genet. 135, 359–362 (2016)
Morgan, P., Van Der Graaf, P.H., Arrowsmith, J., Feltner, D.E., Drummond, K.S., Wegner, C.D., Street, S.D.: Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug. Discov. Today 17, 419–424 (2012)
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817–2826 (2004)
Panagiotou, O.A., Ioannidis, J.P.: Genome-wide significance project. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int. J. Epidemiol. 41(1), 273–86 (2012)
Pe’er, I., Yelensky, R., Altshuler, D., Daly, M.: Estimation of the multiple testing burden for Genomewide association studies of nearly all common variants. Genet. Epidemiol. 32, 381–385 (2008)
Shyr, D., Liu, Q.: Next generation sequencing in cancer research and clinical application. Biol. Proced. Online 15, 4 (2013)
Storey, J.D.: A direct approach to false discovery rates. J. Roy. Stat. Soc. 64, 479–498 (2002)
TESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial (2016). http://ir.tesarobio.com/releasedetail.cfm?releaseid=977524
Thomas, D.W., Burns, J., Audette, J., Carroll, A., Dow-Hygelund, C., Hay, M.: Clinical Development Success Rates 2006–2015. June 2016. https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf
Valdar, W., Holmes, C.C., Mott, R., Flint, J.: Mapping in structured populations by resample model averaging. Genetics 182, 1263–1277 (2009)
Wetterstrand, K.A.: DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) (2016). www.genome.gov/sequencingcostsdata. Accessed 23 Dec 2016
Zhang, W., Korstanje, R., Thaisz, J., Staedtler, F., Harttman, N., Xu, L., Feng, M., Yanas, L., Yang, H., Valdar, W., Churchill, G.A., DiPetrillo, K.: Genome-wide association mapping of quantitative traits in outbred mice. G3: Genes Genomes Genet. 2(2), 167–174 (2012)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Pfizer, Inc.
About this paper
Cite this paper
Zhang, W. (2019). Leveraging Omics Biomarker Data in Drug Development: With a GWAS Case Study. In: Liu, R., Tsong, Y. (eds) Pharmaceutical Statistics. MBSW 2016. Springer Proceedings in Mathematics & Statistics, vol 218. Springer, Cham. https://doi.org/10.1007/978-3-319-67386-8_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-67386-8_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67385-1
Online ISBN: 978-3-319-67386-8
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)